Cases of B-cell lymphoma with bone marrow involvement have a very poor prognosis, with a five-year survival rate of 10%, while those with no bone marrow involvement have a five-year survival rate of about 62% to 70%. B-cell lymphomas are solid tumors arising from the body’s B-cells and are classified as inert and aggressive lymphomas according to their natural course. According to the pathology, they are divided into Hodgkin’s lymphoma and non-Hodgkin’s lymphoma, and Hodgkin’s and non-Hodgkin’s lymphoma have numerous subtypes respectively. 1. Inert lymphoma progresses slowly and is able to maintain a long-term progression-free state, but it does not heal on its own. 2. Aggressive lymphoma usually progresses rapidly and requires radiotherapy, chemotherapy and combined radiotherapy, and hematopoietic stem cell transplantation if available. Drugs include vincristine, cyclophosphamide and so on. In brief, the prognosis of type B lymphoma depends on its typing, staging and grading, and specific diagnosis and treatment should be carried out under the guidance of physicians.